Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 21, Issue 2-3, Pages 197-203Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2010.02.005
Keywords
PVS-RIPO; Glioblastoma multiforme; Central nervous system
Categories
Funding
- NCI NIH HHS [R01 CA124756, R01 CA124756-04] Funding Source: Medline
Ask authors/readers for more resources
PVS-RIPO is a genetically recombinant, non-pathogenic poliovirus chimera with a tumor-specific conditional replication phenotype. Consisting of the genome of the live attenuated poliovirus type 1 (Sabin) vaccine with its cognate IRES element replaced with that of human rhinovirus type 2. PVS-RIPO displays an inability to translate its genome in untransformed neuronal cells, but effectively does so in cells originating from primary tumors in the central nervous system or other cancers. Hence, PVS-RIPO unleashes potent cytotoxic effects on infected cancer cells and produces sustained anti-tumoral responses in animal tumor models. PVS-RIPO presents a novel approach to the treatment of patients with glioblastoma multiforme, based on conditions favoring an unconventional viral translation initiation mechanism in cancerous cells. In this review we summarize advances in the understanding of major molecular determinants of PVS-RIPO oncolytic efficacy and safety and discuss their implications for upcoming clinical investigations. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available